InflaRx N.V. Reports Q1 2024 Financial Loss
Company Announcements

InflaRx N.V. Reports Q1 2024 Financial Loss

Inflarx N.V. (IFRX) has released an update.

InflaRx N.V., a biopharmaceutical company based in Germany and the Netherlands, reported a comprehensive loss for the first quarter of 2024. The unaudited financial statements showed an operating loss and a negative income for the period, despite generating revenues. The company’s total assets, including cash and cash equivalents, remained substantial.

For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInflaRx Reports Q3 2024 Financial Results and Progress
TipRanks Auto-Generated NewsdeskInflaRx Reports Rising Revenue Amidst Significant Losses
TheFlyInflaRx reports Q3 EPS (EUR 0.30) vs. (EUR 0.13) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App